Bioinformatics Postdoctoral Positions Available

We are recruiting for talented individuals to join our data mining team in bioinformatics. You will work closely with our drug discovery teams to analyze DNA/protein sequences and microarray-based gene expression data to elucidate gene function and identify therapeutic targets. You will provide expertise in the application of advanced bioinformatics tools and in-depth knowledge of public and proprietary data sources. Requires a Ph.D. in a Molecular Biology or related field. Current graduates with a proven research record are strongly encouraged to apply. Expert knowledge in a wide variety of sequence analysis software (GCG, BLAST, HMMER, Gene prediction, etc.) and programming experience in C/C++, Java, Perl, HTML and SQL in UNIX and Windows NT environments are plus.

Please send résumé to: priljhr@prius.jnj.com or xliu3@prius.jnj.com

Xuejun Liu, Ph.D.
Consultant, Bioinformatics
The RW Johnson
Pharmaceutical Research Institute
3210 Merryfield Row
San Diego, CA 92121-1126
Phone: 858-784-3250
Fax: 858-450-2002

 

Molecular, Cell & Developmental Biology

In-House Seminar Series 2000-2001

Presents:

Dr. Xuejun Liu
Consultant/Senior Scientist, Bioinformatics
The RW Johnson Pharmaceutical Research Institute

"Data mining: from microarray expression database to functional genomics"

Abstract:

"The rapidly accumulating gene expression data using the high-throughput microarray technology provides a valuable resource to functionally characterize the complete catalogue of genes predicted by human genome draft. However, it has been, and will continue to be a big challenge for biologists to extract biological significance from the massive expanse of raw expression data. Here I exhibit several examples of data analysis results to exploit the functionality of our in-house expressional database based on cDNA microarray technology. 1) building a prototype of the molecular anatomy of rat brain by analyzing expression profiles of individual neurons isolated by laser capture; 2) extraction of gene signatures to classify different tissues in mice; 3) assessment of the efficacy of alternative treatment schema of Erythropoietin in a large-scaled clinical study. A more comprehensive database of expressional references is being created to systematically classify genes of interests, and this will facilitate the identification of new genetic targets for drugs."

Thursday, May 31, 2001
12 Noon
1601 Molecular Sciences Bldg. [please note room change]